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Abstract
 
Much of the pathology of malaria is mediated by inflammatory cytokines (such as interleukin
12, interferon 
 

 
, and tumor necrosis factor 
 

 
), which are part of the immune response that kills
the parasite. The antiinflammatory cytokine transforming growth factor (TGF)-
 
 
 
plays a crucial
role in preventing the severe pathology of malaria in mice and TGF-
 
 
 
production is associated
with reduced risk of clinical malaria in humans. Here we show that serum-free preparations of
 
Plasmodium falciparum
 
, 
 
Plasmodium
 
 
 
yoelii
 
 17XL, and 
 
Plasmodium berghei
 
 schizont-infected erythrocytes,
but not equivalent preparations of uninfected erythrocytes, are directly able to activate latent
TGF-
 
 
 
(LatTGF-
 

 
) in vitro. Antibodies to thrombospondin (TSP) and to a 
 
P. falciparum 
 
TSP-
related adhesive protein (PfTRAP), and synthetic peptides from PfTRAP and 
 
P. berghei
 
 TRAP
that represent homologues of TGF-
 
 
 
binding motifs of TSP, all inhibit malaria-mediated
 
TGF-
 
 
 
activation. Importantly, TRAP-deficient 
 
P. berghei
 
 parasites are less able to activate
LatTGF-
 
 
 
than wild-type parasites and their replication is attenuated in vitro. We show that
activation of TGF-
 
 
 
by malaria parasites is a two step process involving TSP-like molecules
and metalloproteinase activity. Activation of LatTGF-
 
 
 
represents a novel mechanism for direct
modulation of the host response by malaria parasites.
Key words: parasitic protozoa • malaria, 
 
falciparum
 
 • transforming growth factor 
 
 
 
• 
matrix metalloproteinases • thrombospondin 1
 
Introduction
 
Much of the overt pathology associated with parasitic in-
fections is immune mediated. In the case of malaria, para-
site killing requires the production of inflammatory cyto-
kines that can have deleterious systemic effects. Thus,
understanding how proinflammatory cytokines are regu-
lated during infection is crucially important for improving
malaria therapy and for designing safe and effective malaria
vaccines.
In murine malaria infections, TNF-
 
 
 
and IFN-
 
 
 
act
synergistically to induce macrophages to phagocytose para-
sitized red blood cells and release nitric oxide, which is
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Abbreviations used in this paper:
 
 huLatTGF-
 

 
, latent human TGF-
 

 
; LAP,
latency-associated protein; LatTGF-
 

 
, latent TGF-
 

 
; MMP, metallo-
proteinase; PbTRAP, 
 
P. berghei
 
 thrombospondin-related adhesive protein;
Pb TRAP ko, PbTRAP knockout; Pb WT, wild-type 
 
P. berghei
 
; PfSL, 
 
P.
falciparum
 
 schizont lysate; PfTRAP, 
 
P. falciparum
 
 thrombospondin-related
adhesive protein; pRBC, parasitized RBC; rHuTSP-1, recombinant human
thrombospondin 1; rLatTGF-
 

 
, recombinant latent human TGF-
 

 
; TSP,
thrombospondin; uRBC, uninfected RBC.
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involved in parasite killing and protection from severe dis-
ease (1). The ability to mount a rapid IL-12, IFN-
 

 
, or
TNF-
 
 
 
response is essential for survival but overproduc-
tion of IFN-
 

 
, TNF-
 

 
, or lymphotoxin-
 
 
 
predisposes to
severe pathology (2, 3). Essentially the same pattern is seen
in human malaria: TNF-
 

 
, IFN-
 

 
, and nitric oxide are as-
sociated with rapid resolution of fever and parasite clear-
ance (4–7), but severe 
 
Plasmodium falciparum
 
 malaria is ac-
companied by high levels of circulating TNF-
 
 
 
(8, 9) and
IFN-
 
 
 
secretion is associated with fever (7, 10). The im-
munomodulatory cytokines IL-10 and TGF-
 
 
 
play a key
role in limiting the pathology of malaria (11). Treatment of
infected mice with neutralizing antibody to TGF-
 
 
 
exacer-
bates the virulence of lethal 
 
Plasmodium berghei
 
 strains and
transforms a normally resolving 
 
Plasmodium chabaudi cha-
baudi
 
 infection into a lethal one (12). Conversely, treatment
of 
 
P. berghei
 
–infected mice with recombinant TGF-
 
 
 
up-
regulates IL-10, down-regulates TNF-
 

 
, slows the rate of
parasite replication, and extends survival (12). In C57BL/6
mice infected with the normally nonlethal 
 
P. chabaudi
 
,
mortality is increased in IL-10–deficient (IL-10
 

 
/
 

 
) mice
(13) and mortality is further exacerbated by neutralization
of TGF-
 
 
 
(14).
Similar data are now emerging from human studies.
Symptomatic 
 
P. falciparum
 
 patients have lower than normal
levels of circulating TGF-
 
 
 
(15, 16) and we have recently
shown that the risk of febrile illness is associated with high
ratios of IFN-
 

 
, TNF-
 

 
, or IL-12 to TGF-
 
 
 
(7). We con-
clude that TGF-
 
 
 
plays an essential role in down-regulat-
ing the production of potentially pathogenic proinflamma-
tory cytokines. However, in at least one murine model of
malaria infection (
 
Plasmodium yoelii
 
 17XL infection in C57/
BL6 mice), a very early burst of active TGF-
 
 
 
serves to
down-modulate the normal early inflammatory cytokine
response, leading to failure to control parasite growth and
death of the mice within 6 d (17). Thus, the outcome of
infection depends on the timing of TGF-
 
 
 
induction and
the ability of a pathogen to modulate the host TGF-
 
 
 
re-
sponse may modify the virulence of the infection.
TGF-
 
 
 
is constitutively produced by a wide range of
cells and its activity is regulated primarily by controlling
the site and rate of activation of latent TGF-
 
 
 
(LatTGF-
 

 
)
to its biologically active form (for review see reference 18).
TGF-
 
 
 
is stored inside the cell as a disulfide-bonded
homodimer that is noncovalently bound to a disulfide-
bonded, homodimeric latency-associated protein (LAP)
and, at least in platelets, to a monomeric LatTGF-
 
 
 
bind-
ing protein. Binding of the cytokine to its receptor re-
quires removal of LatTGF-
 
 
 
binding protein and LAP, a
process that is catalyzed in vivo by a number of agents in-
cluding plasmin, cathepsins, calpain, and thrombospondin
(TSP; 19, 20). TSP appears to be an important activator of
TGF-
 
 
 
in that TSP null mice produce active TGF-
 
 
 
only
after treatment with a TSP peptide containing the TGF-
 

 
–activating domain and this peptide rescues TSP null
mice from lethal, multifocal inflammatory disease (21).
Activation of TGF-
 
 
 
by TSP is a two step process requir-
 
ing initial attachment of TSP to TGF-
 
 
 
via the GGW-
SHW motif of TSP, followed by cleavage by a (K)RFK
motif (22). However, alternative mechanisms of TGF-
 

 
activation clearly exist as platelet-derived TGF-
 
 
 
can be
activated in the absence of TSP (23). Here we report the
results of a series of experiments designed to test the hy-
pothesis that 
 
Plasmodium
 
-encoded molecules modulate
TGF-
 
 
 
activation. Importantly, our study demonstrates
that malaria parasites contain endogenous TGF-
 

 
–activat-
ing moieties that may play a role in modulating the out-
come of malaria infections.
 
Materials and Methods
 
Malaria Parasites. P. falciparum
 
 parasites of the 3D7 strain were
grown in A
 
 
 
human erythrocytes and mature schizonts were har-
vested as previously described (24). Cultures were routinely
screened for mycoplasma contamination by PCR (BioWhittaker)
and shown to be mycoplasma free. Schizont-infected erythrocytes
were washed three times in serum-free medium to remove endog-
enous serum proteases and other proteins. Parasitized erythrocytes
were used either as intact (live, parasitized RBCs [pRBCs]) or as a
sonicated 
 
P. falciparum 
 
schizont lysate (PfSL). Similarly treated, un-
infected erythrocytes (uninfected RBCs [uRBCs]) were used as a
control. In some experiments, pRBCs were allowed to undergo
schizont rupture in vitro and the supernatant from the ruptured
cells was used (pRBC supernatant).
Wild-type 
 
P. berghei
 
 (Pb WT) NK65, 
 
P. berghei 
 
TSP-related
adhesive protein (PbTRAP) knockout parasites (Pb-TRAP-
INT2) lacking the 5
 
 
 
promoter sequences and the first 22 codons
of the TRAP coding sequence (PbTRAP knockout [Pb TRAP
ko]; reference 25), and 
 
P. yoelii
 
 17XL schizonts were prepared
from the blood of infected C57BL6 mice. Mice were infected
with 10
 
4 
 
pRBCs of each species. When maximum parasitemia
was reached, mice were exsanguinated by cardiac puncture and
pRBC purified by centrifugation through 72% Percoll. Schizont-
infected erythrocytes were washed extensively in serum-free PBS
and used either whole or after sonication (pRBC lysate).
 
TGF-
 
 
 
Activation Assay.
 
The TGF-
 
 
 
activation assay is a
modified version of the assay described by Schultz-Cherry et al.
(26). Parasites (intact or lysed) were diluted in PBS containing
0.1% BSA to a final concentration of between 10
 
3 
 
and 10
 
7 
 
pRBCs
per ml. Uninfected red cells were used at equivalent concentra-
tions. Either purified, platelet-derived latent human TGF-
 
 
 
(hu-
LatTGF-
 

 
), which comprises TGF-
 
 
 
plus the latency-associated
peptide LAP (Sigma-Aldrich), or recombinant latent human
TGF-
 
 
 
(rLatTGF-
 

 
), also comprising TGF-
 
 
 
plus LAP (R&D
Systems), was added to parasites at a final concentration of 100
ng/ml and incubated for 2 h at 37
 

 
C. The contents of each well
were then centrifuged (13,000 rpm for 60 s) to pellet the parasite
material and the supernatants were tested for active TGF-
 
 
 
by
ELISA. Recombinant human TSP-1 (rHuTSP-1; Sigma-Aldrich),
at a concentration of 50 ng/ml, was used as a positive control.
The maximum releasable concentration of active TGF- was de-
termined by acid activation of LatTGF-, as previously described
(12). All assays were performed in triplicate.
TGF- Inhibitors. To determine their ability to block TGF-
activation, potential inhibitors were added to the LatTGF- at
the start of the assay, before addition of the parasites. Mouse
monoclonal antibody (clone TSP-B7) to human TSP-1 (anti–
TSP-1; Sigma-Aldrich) was used at concentrations from 0.01 to
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20 	g/ml. Affinity-purified polyclonal sheep antibody, 1.5, and
mouse monoclonal antibody, 19F7, to P. falciparum TSP-related
adhesive protein (PfTRAP) were provided by K. Robson (Uni-
versity of Oxford, Oxford, United Kingdom) and A. Crisanti
(Imperial College, London, United Kingdom), respectively. An-
tibodies were dialyzed against PBS to remove preservatives and
diluted to final concentrations of up to 4 	g/ml. Dialyzed control
antibodies, polyclonal sheep IgG (Sigma-Aldrich) and mouse IgG
(R&D Systems), and a monoclonal antibody X509 to P. falci-
parum merozoite protein 1 (provided by M. Blackman, National
Institute for Medical Research, London, United Kingdom), were
used as negative controls. Protease inhibitors were obtained from
Sigma-Aldrich (benzamidine, E-64, phenanthroline, apstatin,
calpain inhibitor, phosphoramidon, bestatin, APMSF, and EDTA)
or Calbiochem (metalloproteinase [MMP]2 inhibitor, MMP2/
MMP9 inhibitor, and GM1489).
Synthetic Peptides. N-acetyl peptides, 8–34 residues long, rep-
resenting sequences of PfTRAP and PbTRAP, each with an
additional COOH-terminal cysteine, were synthesized by con-
ventional solid phase techniques. Peptides were purified by RP-
HPLC in gradients of CH3CN (Merck) in 0.1% trifluoroacetic
acid (Applied Biosystems), lyophilized, reconstituted in PBS, and
dialyzed before use. Peptide identities were confirmed by matrix-
assisted laser desorption time-of-flight mass spectroscopy. The
sequences of the peptides are: PfTRAP-1, VIGPFMK-
AVCVEVEKTASCGVWDEWSPCSVTCGK; PfTRAP-2,
SCGVWDEWSPCSVTCGK; and PbTRAP, KVALCGKWEE-
WSECSTTCDN. The underlined amino acid sequences indicate
the region homologous to the TSP-1 TGF-–binding motif,
GGWSHW.
TGF- ELISA. ELISA assays were conducted as previously
described (27) using chicken anti–human TGF--1 as the coating
antibody, monoclonal mouse anti–hTGF-1, anti–hTGF-2,
and anti-hTGF-3 as the detecting antibody, and recombinant
human TGF-1 as the standard (all reagents from R&D Systems).
These antibodies detect epitopes that are revealed only in the bio-
active form of TGF- but not in the inactive (latent) form of the
molecule. Thus, the assay measures only bioactive TGF-. Su-
pernatants were not acid activated before testing.
Zymography. 4 
 107 pRBCs were suspended in Tris-glycine
SDS sample buffer (0.25 M Tris-Cl, 20% glycerol, 5% SDS,
0.05% bromophenol blue, pH 6.8), sonicated, centrifuged at
10,000 g for 20 min at 4C, and applied to a 10% zymogram gel
(Invitrogen). The gel was electrophoresed at 125 V for 90 min
and proteins were renatured by incubation of the gel in 25% Tri-
ton X-100 in dH2O. The renatured gel was incubated in devel-
oping buffer (Tris base 1.21 g/l, Tris HCl 6.3 g/l, NaCl 11.7 g/l,
CaCl2 0.74 g/liter, Brij 3.5% [wt/vol] in dH2O) for 16 h at 37C
and stained with Coomassie blue.
Gelatin-Agarose Affinity Chromatography. P. falciparum schiz-
ont-infected erythrocytes (pRBCs) were suspended at a con-
centration of 4 
 107 pRBCs per ml in 20 mM Tris-HCl, pH
7.5, containing 0.15 M NaCl, 1% Triton X-100, plus protease in-
hibitors leupeptin, E64, and antipain (all used at 25 	g/ml; all
from Sigma-Aldrich), and briefly sonicated. The sonicate was
spun down (10,000 g for 20 min at 4C) and 200 	l of the super-
natant was mixed with an equal volume of gelatin-agarose resin
(Sigma-Aldrich) and incubated on ice for 2 h. The resin was spun
down and washed three times in 50 mM Tris-HCl, pH 7.5, with
0.5 M NaCl, 5 mM CaCl2, 0.05% Brij-35, and 0.02% NaN3 (all
from Sigma-Aldrich). Bound proteins were released by incuba-
tion on ice for 30 min in 100 	l 7.5% DMSO in Tris-Brij buffer.
The supernatant was dialyzed against 50 mM Tris-HCl, pH 7.5,
with 5 mM CaCl2 and 0.01% Brij-35, and concentrated using a
Figure 1. Activation of huLat-
TGF- by Plasmodium spp. (a) Hu-
LatTGF- was incubated for 2 h
with P. falciparum schizonts (pRBC)
or uRBCs (uRBC) at concentrations
of 105, 106, or 107 erythrocytes per
ml, or medium alone. HuLatTGF-,
platelet-derived, latent human
TGF-; rLatTGF-, recombinant
latent human TGF-. (b) HuLat-
TGF- was incubated with 4 

103–4 
 107 P. falciparum pRBCs/
ml, the supernatant from an equiva-
lent number of rupturing schizonts
(pRBC supernatant) or equal num-
bers of uRBCs (uRBC). (c) HuLat-
TGF- was incubated with 106 P.
falciparum pRBCs/ml, 106 uRBCs/ml,
or medium alone in the presence or
absence of 50 ng/ml rHuTSP-1. (d)
HuLatTGF- was activated by acid-
ification or incubated with 106 P.
falciparum, P. berghei, or P. yoelii
pRBCs or equivalent concentrations
of human or mouse uRBCs. In all
cases the concentration of bioac-
tive TGF- in cell supernatants
was assayed by ELISA. Error bars
represent SEM of triplicate assays.
In a, b, and c, acid activation of
HuLatTGF- generated 1,970 
109 pg/ml (mean  SEM) active
TGF-.
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minidialysis unit (Pierce Chemical Co.). The supernatant was
tested for TGF-–activating capacity and for the presence of ge-
latinases by zymography.
Results
P. falciparum Schizont-infected Erythrocytes Activate rLat-
TGF- In Vitro. Purified, platelet-derived huLatTFG-
and rLatTGF- were incubated with varying concentrations
of pRBCs, uRBCs, or pRBC supernatant for 2 h and the
release of bioactive TGF- into the medium was assayed by
ELISA. The huLatTGF- and rLatTGF- were both acti-
vated, in a dose-dependent manner, by pRBCs but not by
uRBCs (Fig. 1 a). However, the rLatTGF- preparation ap-
peared to contain some spontaneously active TGF-, mak-
ing the effects of specific activators and inhibitors less easy to
interpret. Thus, platelet-derived huLatTGF- was used in all
subsequent assays. Concentrations of active TGF- released
by pRBC were of the same order of magnitude as those re-
leased by acid activation (mean, SEM 1970  109 pg/ml).
LatTGF- was activated both by pRBCs and pRBC su-
pernatant (Fig. 1 b), suggesting that the TGF-–activating
component of the parasite is released at schizont rupture.
The amount of bioactive TGF- liberated by pRBCs was
shown to be similar in magnitude to that liberated by
rHuTSP-1 (Fig. 1 c). Incubation of LatTGF- with rHu-
TSP-1 and pRBCs together released only slightly more
bioactive TGF- than incubation with either activator
alone, suggesting that the mechanisms of activation of Lat-
TGF- by pRBCs and TSP might be similar.
Specific activation of LatTGF- was seen at parasite
concentrations as low as 103–104 pRBCs/ml (Fig. 1 b),
which is three orders of magnitude lower than the parasite
densities typically associated with the onset of human clini-
cal malaria, indicating that the effect is seen at physiologi-
cally relevant parasite densities. However, variation was
observed between experiments in the amount of TGF-
released by a given concentration of pRBCs (varying from
400 to 2,500 pg/ml from 106 pRBCs). We believe that
this relates to the exact stage of maturity of the schizonts
and the extent to which they undergo schizont rupture
during the incubation period.
Other Plasmodium spp Also Possess TGF-–activating En-
zymes. To determine whether TGF- activation was a
unique feature of P. falciparum, or whether other Plasmo-
dium spp might also be able to interact with host cytokines,
we compared schizont sonicates of P. falciparum with simi-
lar preparations of two rodent malaria parasites, P. berghei
NK65 and P. yoelii 17XL, for their ability to activate TGF-
(Fig. 1 d). uRBC sonicate had little or no activating effect.
Both P. berghei pRBC and P. yoelii pRBC sonicates
showed very marked TGF-–activating effects. Levels of
TGF- released by the murine parasites were significantly
higher than those released by P. falciparum.
Anti-TSP Antibodies Partially Inhibit the TGF-–activating
Capacity of P. falciparum. LatTGF- was incubated with
106 P. falciparum pRBCs, 106 uRBCs, or 50 ng/ml
rHuTSP-1 in the presence or absence of a neutralizing an-
tibody to human TSP-1 (Fig. 2). Anti-TSP antibodies in-
hibited the activation of LatTGF- by both TSP-1 itself
and by pRBCs (Fig. 2 a). The effects of anti-TSP antibody
were dose dependent and at a concentration of 0.25 	g/
ml, the anti–TSP-1 antibody inhibited the effects of pRBC
by 70% in comparison to the uRBC control (Fig. 2 b).
The control antibody did not inhibit TGF- activation.
These data suggest that the TGF-–activating activity of
pRBCs is mediated, in part, by a TSP-related protein that
is recognized by anti-TSP antibodies.
TGF-–activating Molecules of P. falciparum Show Func-
tional Homology to TSP-1. A number of P. falciparum mol-
ecules have been identified that share varying levels of
homology with HuTSP-1. Of these, perhaps the best char-
acterized is PfTRAP (28). TRAP is expressed in preeryth-
rocytic and erythrocytic stages of the parasite life cycle
where it induces both cellular and humoral immune re-
sponses (29, 30). PfTRAP shares several regions of homol-
ogy with TSP-1, including the highly conserved WSPCS-
VTCG motif, a GXWXXW sequence in which the X’s are
conservative substitutions for the TGF-–binding GGW-
SHW motif of TSP-1, and a module that facilitates binding
to proteoglycans, which are powerful regulators of TGF-
activity. Therefore, we wondered whether PfTRAP might
mediate activation of LatTGF-.
Figure 2. Antibodies to human TSP-1 inhibit TGF- activation by
pRBCs. (a) HuLatTGF- was incubated for 2 h with 106/ml P. falciparum
pRBCs or uRBCs, or 50 ng/ml TSP-1 in the presence or absence of
20 	g/ml neutralizing anti–TSP-1 antibody. (b) HuLatTGF- was in-
cubated with 106/ml pRBCs or uRBCs in the presence of varying con-
centrations of neutralizing anti–TSP-1 antibody or an isotype-matched
control antibody. The concentration of bioactive TGF- in cell supernatants
was assayed by ELISA. Error bars represent SEM of triplicate assays.
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LatTGF- was incubated with pRBCs or uRBCs in the
presence or absence of varying concentrations of two
different anti-TRAP antibodies or isotype-matched con-
trol antibodies. The first, a sheep polyclonal IgG anti-
TRAP1.5, was raised against the NH2-terminal half of the
TRAP molecule, upstream of the TSP-like domain (31).
The other, a murine IgG monoclonal antibody 19F7, rec-
ognizes an epitope in the extreme C terminus of the
TRAP molecule (31). The polyclonal anti-TRAP1.5 in-
hibited pRBC-induced activation of TGF- by 60% at a
concentration of 4 	g/ml, whereas monoclonal antibody
19F7 completely inhibited TGF- activation at a similar
concentration (Fig. 3 a). Neither the isotype-matched con-
trol antibodies nor an irrelevant malaria-specific monoclo-
nal antibody (monoclonal antibody X509, which binds to
P. falciparum merozoite surface protein 1; unpublished data)
had any effect on TGF- activation.
The inhibition of pRBC-mediated activation of Lat-
TGF- by antibodies to both human TSP-1 (Fig. 2) and
PfTRAP (Fig. 3 a) indicated that PfTRAP might be a
functional homologue of TSP-1 with respect to TGF- ac-
tivation. Both PfTRAP and PbTRAP contain sequences
with homology to the GGWSHW TGF-–binding do-
main of TSP-1. The PfTRAP sequence is GVWDEW and
the PbTRAP sequence is GKWEEW. Therefore, we
tested the ability of synthetic peptides representing these se-
quences to activate LatTGF- in vitro. HPLC-purified and
dialyzed peptides were diluted in PBS plus 0.5% BSA and
added to LatTGF- at concentrations from 0.2 to 5.0 	g/
ml in the presence or absence of pRBC.
In the absence of PfSL, none of the peptides showed any
significant TGF-–activating capacity (not depicted).
However, the PfTRAP-2 and PbTRAP peptides were able
to inhibit PfSL-mediated activation of LatTGF- in a
dose-dependent manner. The longer PfTRAP-1 peptide
also inhibited TGF- activation but the effect was not dose
dependent at the range of concentrations tested (Fig. 3 b).
A control preparation, comprising the flow through from
the HPLC column, had no effect on PfSL-mediated TGF-
activation (not depicted). These data suggest that the syn-
thetic peptides are able to bind to relevant sequences in
LatTGF- and, although not able to directly activate it,
may block the access of PfSL-derived molecules, strongly
supporting the notion that TGF- activation by PfSL is
mediated by TSP-like molecules.
As a final confirmation that TRAP mediates in vitro acti-
vation of LatTGF-, we compared the ability of Pb WT and
TRAP-deficient P. berghei (Pb TRAP ko) to activate TGF-
(Fig. 3 c). Pb WT pRBCs very efficiently activated LatTGF-,
as seen previously, whereas activation was markedly lower
for Pb TRAP ko pRBC. Similar results were obtained for
pRBC lysates (not shown here but apparent in Fig. 5 d).
As we have recently shown (17) that rapid induction of
bioactive TGF- very early in a blood stage malaria infec-
Figure 3. Plasmodium TRAP is
involved in the activation of TGF-
by pRBCs. (a) HuLatTGF- was
incubated with 106/ml P. falciparum
pRBCs or uRBCs in the presence
of varying concentrations of anti-
TRAP antibodies 1.5 and 19F7, or
with isotype-matched control mouse
(mIgG) or sheep (sIgG) antibodies.
(b) Synthetic peptides, at concentra-
tions of 0.2–5.0 	g/ml, were added
to in vitro TGF- activation assays
in the presence of PfSL at a concen-
tration of 2 
 106 parasites/ml. (c)
Activation of LatTGF- was com-
pared for Pb WT pRBCs (Pb WT)
and for PbTRAP knockout (Pb
TRAP ko). (d) Outbred CD1 mice
(n  6 per group) were infected
with either wild-type or TRAP
knockout P. berghei pRBCs (104
pRBCs per mouse) on day 0 and
parasitemia was monitored by mi-
croscopy. Mice were humanely
killed when parasitemia reached
80%. , P. berghei wild-type; , Pb
TRAP ko (five mice); , Pb
TRAP ko (one mouse). Infections
in all mice became patent on day 3
after inoculation. The concentration
of bioactive TGF- in cell superna-
tants was assayed by ELISA. Error
bars represent SEM of triplicate assays.
Acid activation of HuLatTGF-
generated 2,040  120 pg/ml
(mean  SEM) active TGF-.
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tion suppresses production of the protective cytokine
IFN- and leads to a highly virulent infection, we consid-
ered that the failure of Pb TRAP ko parasites to activate
TGF- might lead to an attenuated phenotype in vivo.
Infections with Pb WT and Pb TRAP ko parasites were
compared in outbred (CD1) and inbred (C57/Bl6) mice.
Although the inherent growth capacity of both wild-type
and knockout lines was similar, as evidenced by the time
from inoculation to patency and the exponential growth
of both lines in the 3 d before death, PbTRAP ko infec-
tions were markedly attenuated in comparison to Pb WT
infections with parasitemia being kept under control for
the first 10 d after infection. Identical infection patterns
were observed for CD1 mice (Fig. 3 d) and C57/BL6
mice (not depicted) and were reproducible over a number
of passages.
P. falciparum Proteases Also Activate Human TGF-. As
TGF- can also be activated by host proteases (18), we
used the TGF- activation assay to determine whether par-
asite proteases were involved in activation of LatTGF-.
After screening at various concentrations, a selection of
protease inhibitors were compared at a single (optimal)
concentration for their ability to inhibit the activation of
rLatTGF- by P. falciparum pRBCs (Fig. 4 a). In all cases,
pRBCs alone induced bioactive TGF- levels of 1,000
pg/ml, whereas the uRBCs did not increase TGF- levels
above the medium control. In the absence of pRBCs none
of the inhibitors had any effect on TGF- activation. Two
of the enzyme inhibitors, E-64, a cysteine protease inhibi-
tor, and the calpain inhibitor, had no effect on TGF- acti-
vation by pRBCs. Benzamidine and APMSF, both serine
protease inhibitors, partially inhibited pRBC-induced
TGF- activation (by 50 and 35%, respectively). How-
ever, TGF- activation was completely or partially blocked
by o-phenanthroline, phosphoramidon, EDTA, and besta-
tin, all of which are MMP inhibitors. Apstatin, a membrane
aminopeptidase inhibitor, also completely blocked TGF-
activation by pRBC.
The inhibitory activity of o-phenanthroline was dose-
dependent, with a concentration of 1	M reducing levels of
active TGF- to levels seen with uRBC (Fig. 4b). Three
additional MMP inhibitors were tested for their ability to
block pRBC-induced TGF- activation. An MMP-2 in-
hibitor (MMP-2Pi) had modest effects on TGF- activa-
tion but a dual MMP-2/MMP-9 inhibitor (MMP2/9i) and
GM1489 (a broad spectrum MMP inhibitor) completely
blocked TGF- activation at concentrations of 2.5 	g/ml
and 2.0 	g/ml respectively; 50% inhibition was observed at
concentrations of 0.025 	g/ml and 0.2 	g/ml respectively.
These data indicate that MMPs are required for P. falci-
parum-mediated activation of LatTGF-.
TGF-–activating Proteases of P. falciparum Bind to Gelatin
and Have Gelatinase Activity. One feature of MMPs is that
they bind to, and cleave, gelatin. Zymography of PfSL
confirmed the presence of gelatinase activity in infected but
not uninfected red cells (Fig. 5 a). Two clear bands were
seen, one of which had a molecular weight of 55 kD.
This may be the P. falciparum equivalent of a heat shock
protein with MMP activity described for Plasmodium vivax
(32). A similar sized band was detected for P. berghei (Fig. 5
b, lanes 1 and 2). Lysates of P. falciparum and P. berghei
pRBCs were affinity purified on gelatin-agarose and eluates
were tested for their ability to activate LatTGF- in vitro.
For P. berghei, the gelatin-purified material was enriched in
the 55-kD gelatinase activity and, although less active than
the crude lysate, this material retained significant TGF-–
activating activity (Fig. 5 c). Similar results were obtained
with P. falciparum lysate.
Interestingly, gelatin-agarose–purified and –eluted mate-
rial from Pb TRAP ko parasites was significantly less able
to activate TGF- than material from Pb WT parasites
Figure 4. P. falciparum proteases activate LatTGF- in vitro. HuLat-
TGF- was incubated with PfSL (equivalent to 106 pRBCs/ml) in the
presence or absence of protease inhibitors. The concentration of bioactive
TGF- in cell supernatants was assayed by ELISA. Error bars represent
SEM of triplicate assays. (a) Protease inhibitors were tested at a single con-
centration: 2 mM benzamidine, 1 	M E-64, 5 	M o-phenanthroline, 5
	M apstatin, 1 	M calpain inhibitor, 5 	M phosphoramidon, 5 	M
bestatin, 20 	M APMSF, and 2.5 mM EDTA. (b) Protease inhibitors
were each tested at three concentrations; GM1489 (0.02, 0.2, and 2.0
mg/ml), o-phenanthroline (0.1, 0.5, and 1.0 	M), MMP2 inhibitor (0.8,
2.0, and 4.0 mg/ml), and MMP2/MMP9 inhibitor (0.025, 0.25, and
2.5 mg/ml). Acid activation of TGF- was used as a positive control
and uRBCs and medium alone were used as negative controls. In these
experiments, acid activation of HuLatTGF- generated 2,143  122 pg/ml
(mean  SEM) active TGF-.
Omer et al.1823
(Fig. 5 d), suggesting that the gelatin-binding components
of the parasite lysate are physically associated with TRAP.
Discussion
Members of the TGF- family are highly conserved
throughout evolution and play essential roles in growth and
development in multicellular organisms, including meta-
zoan parasites. Thus, for example, TGF- or TGF- re-
ceptor homologues have been identified in filarial nema-
todes (33, 34) and components of the TGF- signaling
pathway are functionally conserved in schistosomes (35–
37). The role of TGF- family molecules in growth or de-
velopment of unicellular parasites is less clear but, given the
established role of TGF- in regulating immune responses
to protozoa (for review see reference 11), modulation of
host TGF- signaling pathways might be an effective sur-
vival strategy. For example, the intracellular protozoan Try-
panosoma cruzi induces expression of TGF- and requires
functional expression of TGF- receptors to invade the
host cell (38, 39). The extracellular protozoan, Trypanosoma
brucei, also induces expression of TGF- mRNA (40).
The data presented here indicate that malaria parasites
have adopted an alternative strategy to modulate the effects
of TGF-: directly activating constitutively produced Lat-
TGF- to its bioactive form. Extracellular processing of
LatTGF- is a major control point in regulation of TGF-
function as the signal peptide that targets the mature pro-
tein for secretion is encoded within the LAP (41). Conse-
quently, overexpression of the entire TGF- gene has
minimal consequences but overexpression of a functional
version of the molecule leads to pathology (42).
The ability of malaria parasites to directly activate Lat-
TGF- has potentially important implications. If parasite-
derived molecules are able to activate TGF- in vivo, this
may contribute to limiting the extent of immunopathology
(7, 12) that might be advantageous for the parasite in that it
may ensure that the host survives long enough to transmit
the infection. If so, vaccines need to be designed such that
they do not interfere with this endogenous pathway of im-
mune modulation. More generally, identification of immu-
nomodulatory parasite products may open up new avenues
for chemotherapy. Alternatively, very rapid induction
(within 24 h) of high levels of bioactive TGF-, as is seen
in C57/BL6 mice infected with P. yoelii 17XL (17), may
switch off the early inflammatory cytokine response that is
essential for controlling parasite replication, leading to en-
hanced parasite virulence (43). This hypothesis is supported
by our observation that TRAP-deficient P. berghei, which
does not possess endogenous TGF-–activating capacity, is
initially controlled much more effectively by the host than
is the wild-type parasite. This cannot be attributed to any
inherent defect in the replication of TRAP-deficient para-
sites as the time from inoculation of subpatent numbers of
TRAP-deficient, infected erythrocytes to patency in the
blood is identical for TRAP knockout and Pb WT (this
Figure 5. TGF-–activating moi-
eties of P. falciparum bind to gelatin
and display gelatinase activity. (a) Ly-
sates of 4 
 107/ml P. falciparum
pRBCs or uRBCs were electro-
phoresed on a 10% zymogram gel.
The gel was incubated overnight at
37C and stained with Coomassie
blue. (b) Lysates of P. falciparum
pRBCs and P. berghei pRBCs (lanes
1 and 3) or affinity-purified pRBC
lysates (eluates released from gelatin-
agarose resin by incubation with
DMSO/Tris Brij; lanes 2 and 4) and
control preparations of mouse or
human uRBCs (lanes 5 and 6) were
electrophoresed on a 10% zymogram
gel. The gel was incubated overnight
at 37C and stained with Coomassie
blue. (c) Gelatin-purified lysates of P.
falciparum or P. berghei pRBCs were
compared with crude lysates for their
TGF-–activating activity by ELISA.
Error bars represent SEM of triplicate
assays. (d) Gelatin-purified lysates of
wild-type (Pb WT) and TRAP
knockout (Pb TRAP ko) P. berghei
pRBCs were compared with crude
lysates for their TGF-–activating
activity by ELISA. Assay of lysates
alone confirms that pRBC lysates do
not contain TGF-–like compo-
nents. Error bars represent SEM of
triplicate assays.
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study and 25) and, once the infection is established, TRAP
knockout parasites are capable of exponential growth.
Rather, we believe that in the early phase of infection
TRAP knockout parasites fail to activate endogenous
TGF-, allowing induction of a partially protective proin-
flammatory (IFN-) cytokine response (17).
The significance of TGF- activation for survival of pro-
tozoan parasites has also recently been demonstrated for
Leishmania. Leishmania spp are potent inducers of TGF-
(44) and it has recently been reported that cathepsin B–like
cysteine proteases of Leishmania donovani and Leishmania
chagasi can activate rLatTGF- and that induction and acti-
vation of TGF- is causally linked to enhanced parasite
survival within the macrophage (45, 46). In a very different
host–pathogen interaction, that of influenza virus infection,
viral neuraminidase has been shown to activate TGF-,
leading to apoptosis of virus-infected cells and suppression
of T cell activation (47, 48).
In this study we have shown that soluble components of
P. falciparum, P. berghei, and P. yoelii pRBCs are directly
able to activate both native (platelet-derived) and rLat-
TGF-. The activating capacity of P. berghei pRBCs was
always noticeably higher than that of P. falciparum pRBCs,
suggesting that there are interspecies differences in the abil-
ity of malaria parasites to activate TGF-. It remains to be
seen whether these differences correlate with virulence.
TGF- activation involves two distinct parasite-derived
molecules, a homologue of TSP-1 and an MMP. This sug-
gests that the ability of malaria parasites to activate TGF-
has evolved separately from that of Leishmania spp (45, 46).
Activation of the LatTGF- complex can be blocked with
antibodies to human TSP-1 and to PfTRAP and TRAP-
deficient parasites are significantly impaired in their ability
to activate LatTGF-, suggesting that TRAP may mimic
the activity of TSP-1. Region II of PfTRAP shows strong
homology with the type 1 (properdin-like) repeats of hu-
man TSP-1 in which the TGF- binding site has been lo-
calized (22) and is flanked by conserved cysteine residues,
suggesting that the secondary structure around this se-
quence is also conserved (28). TRAP or TRAP-related
molecules thus have the potential to modulate TGF- ac-
tivity in a number of different ways. A monoclonal anti-
body recognizing an epitope in the COOH-terminal re-
gion of PfTRAP was highly effective at low concentrations
of inhibiting TGF- activation and a polyclonal serum rec-
ognizing the NH2-terminal half of the molecule was also
able to inhibit. The effects of anti-TRAP antibodies were
confirmed by showing that PfTRAP and PbTRAP peptide
homologues of the GGWSHW TGF- orientation/bind-
ing domain of TSP also inhibited TGF- activation. This
suggests that TRAP may bind TGF- but, in the absence
of a (K)RFK-like cleavage motif (22), is unable to cause
full activation of the latent molecule. Thus, TRAP is nec-
essary but not sufficient for TGF- activation by malaria
parasites and this study indicates an essential role for MMPs
in addition to TRAP or other TSP homologues. Indeed,
recent reports suggest that TSP alone does not activate
TGF- but depends on the presence of other factors (49,
50) and a recent study has shown that human MMP-2 (ge-
latinase A) binds to TSP (51).
The role of TRAP, rather than other Plasmodium-
derived TSP-like molecules, in TGF- activation was con-
firmed by experiments with transgenic, TRAP-deficient P.
berghei. Although TRAP is primarily expressed in sporozo-
ite stages of the parasite, there are reports of expression of
TRAP or TRAP-like proteins in blood stages of P. falci-
parum (52) and recent data indicate that the PbTRAP pro-
moter is leaky with low levels of promoter activity con-
tinuing in blood stage parasites (Ménard, R., personal
communication). It is possible that differences between
Plasmodium species in levels of TRAP expression by eryth-
rocytic stages might explain the differences that we have
observed in their TGF-–activating capacity.
The proteinase inhibition experiments indicate that
MMP-like components of malaria parasites contribute to
TGF- activation. Specifically, we have shown a role for a
gelatinase B/MMP-9–like but not an MMP-2–like moiety.
We have shown by zymography that both P. falciparum and
P. berghei contain gelatinases. One of these may correspond
to the 55-kD heat shock protein of P. vivax that has previ-
ously been shown to display MMP activity (32). Gelatinase
activity can be enriched by adsorption of parasite extracts
with gelatin-agarose and the enriched material, after elution
from gelatin-agarose, retains the ability to activate TGF-.
Thus, parasite-derived MMPs and TSP-1–like molecules
can activate LatTGF-, however the precise mechanism
remains to be resolved. There are a number of related
models that might explain our findings. In the first model,
parasite-derived proteases cleave TSP-like molecules (such
as TRAP) from the surface membrane of the parasite.
These TSP-like molecules are now free to interact with
soluble TGF- and activate it. In support of this model,
the parasite-derived protease MPP1 of Toxoplasma gondii
cleaves a number of membrane-associated micronemal pro-
teins of T. gondii including TgMIC2 (53), a functional ho-
mologue of Plasmodium TRAP (54). Cleavage takes place
within the transmembrane domain leading to release of sol-
uble protein (53, 55). One class of enzymes that is able to
cleave polypeptides within cell membranes are the site 2
zinc MMPs (56). The transmembrane cleavage motif is
highly conserved in micronemal proteins of apicomplexa,
including PfTRAP, PbTRAP, and circumsporozoite TRAP-
related protein, and PbTRAP can be cleaved by T. gondii
proteases (55), suggesting that the proteolytic enzyme is
functionally conserved. T. gondii MPP1 is constitutively
active on the parasite surface (55), suggesting that the ho-
mologous enzyme in Plasmodium might be expressed on
merozoites and come into contact with plasma proteins at
schizont rupture.
Alternatively, a two step activation process has been de-
scribed for TGF- in epithelial tissues that involves the
binding of the integrin v8 to the RGD motif of LAP
followed by cleavage of LAP by a membrane-type 1-MMP
(MT1-MMP; reference 57). By analogy, PfTRAP or a re-
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lated protein could bind to LAP via the GXWXXW do-
main, allowing a parasite-encoded matrix MMP to then
cleave the latency protein. In a third model, binding and
cleavage of LatTGF- could be mediated by a single bi-
functional molecule such as a member of the disintegrin
and MMP domain TSP type-1 zinc MMP family of en-
zymes (58), which are characterized by the presence of a
variable number of TSP type-1 repeats upstream of MMP
and disintegrin-like domains. Several P. falciparum proteins
appear to contain both MMP domains and TSP type-1 re-
peats. These include TRAP itself, the circumsporozoite
protein, and circumsporozoite TRAP-related protein. The
observation that gelatin-purified material from wild-type
parasites retains TGF-–activating capacity whereas that of
Pb TRAP ko pRBC has very little TGF-–activating ca-
pacity, suggesting that the TRAP and MMP moieties are
linked in some way, tends to support this latter model of
TGF- activation.
In summary, we have described an entirely novel mech-
anism of pathogen-mediated TGF- activation. In contrast
to the mechanisms described for other pathogens, our data
indicate that activation of TGF- by malaria parasites is
similar to endogenous TGF- activation in the mammalian
host, suggesting either conservation of TGF-–activating
mechanisms or convergent evolution. The conservation
within apicomplexan protozoa of the key molecular motifs
required for TGF- activation suggests that these data
might be relevant to other infections, including toxoplas-
mosis. Furthermore, the fact that many different classes of
pathogens (viruses, protozoa, and helminths) have indepen-
dently evolved mechanisms by which to modulate the
TGF- pathway suggests that regulation of TGF- activity
might be a crucial component of pathogen virulence. We
have recently demonstrated that differences in virulence
between strains of the rodent parasite P. yoelii are due to
differential induction of bioactive TGF- (17). It remains
to be seen whether differences in virulence between other
parasite species might also be explained by their relative
ability to regulate TGF- activity.
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